Results 81 to 90 of about 59,251 (307)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

ESC Heart Failure, 2022
Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF–PH).
P. Codina, M. Domingo, E. Barcelo, P. Gastelurrutia, D. Casquete, Joan Vila, Omar Abdul-Jawad Altisent, G. Spitaleri, G. Cediel, E. Santiago-Vacas, E. Zamora, M. Ruiz-Cueto, J. Santesmases, R. de la Espriella, D. Pascual-Figal, J. Núñez, J. Lupón, A. Bayés‐Genís   +17 more
semanticscholar   +1 more source

Non-adherence to cardiovascular pharmacotherapy in Iraq assessed using 8-items Morisky questionnaire and analysis of dried blood spot samples [PDF]

, 2019
open access journalThe study evaluated the non-adherence to selected cardiovascular medications, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, simvastatin and valsartan in Iraqi patients by applying a standardized Morisky questionnaire (8 ...
Alalaqi, Ahmed, Lawson, Graham, Obaid, Yaseen, Tanna, Sangeeta   +3 more
core   +1 more source

Sacubitril/valsartan in the treatment of systemic right ventricular failure

Heart, 2021
Objective Pharmacological options for patients with a failing systemic right ventricle (RV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA (ccTGA) are not well defined.
T. Zandstra, M. Nederend, M. Jongbloed, P. Kiès, H. Vliegen, B. Bouma, L. Tops, M. Schalij, A. Egorova   +8 more
semanticscholar   +1 more source

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial

European Journal of Heart Failure, 2022
We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n = 731) or post‐randomization drop‐in use (n = 425), to evaluate the relationship between the efficacy and safety of combination therapy with ...
M. Senni, W. Alemayehu, D. Sim, F. Edelmann, J. Butler, J. Ezekowitz, A. Hernandez, Carolyn S. P. Lam, C. O'connor, B. Pieske, P. Ponikowski, L. Roessig, A. Voors, C. Westerhout, C. McMullan, P. Armstrong   +15 more
semanticscholar   +1 more source

Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)

European Journal of Heart Failure
Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM).
L. Velicki, Dejana Popović, N. Okwose, A. Preveden, M. Tešić, M. Tafelmeier, S. Charman, F. Barlocco, Guy A. MacGowan, P. Seferovic, Nenad Filipović, A. Ristić, I. Olivotto, L. S. Maier, D. Jakovljevic   +14 more
semanticscholar   +1 more source

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial

European Journal of Heart Failure, 2022
As sacubitril/valsartan may potentiate early natriuresis, expert consensus documents recommend diuretic dose reduction on first initiation. However, there are limited data on the effects of sacubitril/valsartan on the background of varying diuretic ...
S. Chatur, B. Claggett, O. Vardeny, K. Jering, Akshay S. Desai, M. Pfeffer, M. Lefkowitz, J. McMurray, S. Solomon, M. Vaduganathan   +9 more
semanticscholar   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and
Akshay S. Desai, S. Solomon, A. Shah, B. Claggett, J. Fang, J. Izzo, K. Mccague, C. Abbas, Ricardo A. Rocha, G. Mitchell   +9 more
semanticscholar   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways

Scientific Reports, 2022
Hyperthyroidism is associated with cardiac hypertrophy, fibrosis, and increased risk of cardiovascular mortality. Sacubitril/valsartan (LCZ696) is a new combined drug that has shown promise for the treatment of hyperthyroidism-associated heart failure ...
Tarek Khamis, A. Alsemeh, Doaa M. Abdullah   +2 more
semanticscholar   +1 more source